Valuation : Monte Rosa Therapeutics, Inc.

Market Cap 1.22B 1.05B 991M 902M 1.7B 116B 1.71B 11.71B 4.56B 58.94B 4.58B 4.48B 195B P/E 2026 *
-8.81x
P/E 2027 * -7.54x
Enterprise Value 1.22B 1.05B 991M 902M 1.7B 116B 1.71B 11.71B 4.56B 58.94B 4.58B 4.48B 195B EV / Sales 2026 *
22.7x
EV / Sales 2027 * 21.4x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day+2.65%
1 week-1.72%
Current month+2.65%
1 month-13.38%
3 months-27.25%
6 months-19.38%
Current year-8.74%
1 week 13.12
Extreme 13.12
14.57
1 month 13.12
Extreme 13.12
17.17
Current year 13.12
Extreme 13.12
25.77
1 year 4.78
Extreme 4.78
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2020
Chief Tech/Sci/R&D Officer - 17/03/2026
Chief Operating Officer 54 01/03/2021
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 49 01/04/2020
Director/Board Member 57 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/7/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/7/26 Exercice

Chief Operating Officer

13,053 0.0155%
6/7/26 Exercice

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
+2.65%-1.72%+198.12%+130.81% 1.19B
+0.21%-2.69%+1.19%+17.32% 49.81B
+2.09%-0.71%+452.73%+498.77% 44.06B
-1.09%-0.41%+35.40%+15.17% 42.99B
-0.26%-4.71%+17.19%+71.67% 40.88B
-0.48%-0.84%+16.25%+49.80% 33.11B
-1.06%+2.87% - - 17.27B
-1.81%-5.02%+22.65%+113.24% 16.58B
-1.35%-3.40%+10.13%+26.34% 14.63B
-2.05%-5.14%+72.89%+34.69% 13.76B
Average -0.48%-2.07%+91.84%+106.42% 27.43B
Weighted average by Cap. -0.49%-1.88%+95.45%+120.48%

Financials

2026 *2027 *
Net sales 53.67M 46.3M 43.55M 39.67M 74.6M 5.09B 75.01M 515M 200M 2.59B 202M 197M 8.59B 57.07M 49.23M 46.31M 42.18M 79.33M 5.42B 79.76M 547M 213M 2.76B 214M 210M 9.14B
Net income -164M -142M -133M -121M -228M -15.58B -229M -1.58B -613M -7.93B -616M -603M -26.28B -201M -174M -163M -149M -280M -19.11B -281M -1.93B -752M -9.72B -756M -739M -32.23B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
01/09/26 USD 14.31 +2.65% 796,289
31/08/26 USD 13.94 +4.19% 1,109,726
28/08/26 USD 13.38 -6.56% 884,651
27/08/26 USD 14.32 -0.42% 1,081,002
26/08/26 USD 14.38 -1.24% 997,716
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.31USD
Average target price
28.50USD
Spread / Average Target
+99.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock